EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Pancreatic polypeptide is a useful plasma marker for radiographically evident pancreatic islet cell tumors in patients with multiple endocrine neoplasia type 1



Pancreatic polypeptide is a useful plasma marker for radiographically evident pancreatic islet cell tumors in patients with multiple endocrine neoplasia type 1



Surgery (st Louis). 122(6): 1012-1020,.



Background. The usefulness of human pancreatic polypeptide (hPP) as a plasma marker for islet cell neoplasms is controversial We sought to determine the relation between fasting plasma hPP levels and radiographically detectable pancreatic islet cell tumors in patients with multiple endocrine neoplasia type 1 (MEN 1). Methods. Fasting plasma hPP levels were measured prospectively in 202 individuals from 31 independent kindreds with MEN 1. Plasma levels greater than 3.0 times the normal age-specific values were defined as elevated. Patients with elevated plasma hPP levels were evaluated with computed tomographic scanning and magnetic resonance imaging, octreotide scanning, or selective angiography. Results. Twenty-two patients had elevated fasting plasma hPP levels, and 20 of these patients were evaluated radiographically. Pancreatic lesions were detected in 19 patients. A group of eight patients with normal basal fasting plasma hPP levels were evaluated with computed tomography, magnetic resonance imaging, octreotide scanning, or selective angiography based on clinical presentation. One patient in this group had an imaging study that was positive for a pancreatic lesion. Conclusions. The presence of a markedly elevated fasting plasma hPP level in patients with MEN 1 is 95% sensitive and 88% specific for the presence of radiographically detectable pancreatic islet cell tumors.

Accession: 009155194

Download citation: RISBibTeXText

DOI: 10.1016/s0039-6060(97)90203-8

Download PDF Full Text: Pancreatic polypeptide is a useful plasma marker for radiographically evident pancreatic islet cell tumors in patients with multiple endocrine neoplasia type 1



Related references

Pancreatic polypeptide is a useful plasma marker for radiographically evident pancreatic islet cell tumors in patients with multiple endocrine neoplasia type 1. Surgery 122(6): 1012-9; Discussion 1019-20, 1998

Nonrandom expression of polypeptide hormones in pancreatic endocrine tumors. An immunohistochemical study in a case of multiple islet cell neoplasia. Cancer 61(9): 1815-1820, 1988

A case of familial multiple endocrine neoplasia men type i with multiple pancreatic islet cell tumors and multiple parathyroid tumors. Journal of the Japan Diabetes Society 34(3): 251-257, 1991

Molecular mechanisms of neoplasia in multiple endocrine neoplasia type 1-related and sporadic tumors of the pancreatic islet cells. Endocrinology and Metabolism Clinics of North America 23(1): 109-115, 1994

Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients. Clinical Endocrinology 85(3): 400-407, 2016

Pancreatic lesions and hormonal profile of pancreatic tumors in multiple endocrine neoplasia type I. An immunocytochemical study of nine patients. Cancer 57(9): 1824-1832, 1986

Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. European Journal of Endocrinology 148(1): 39-43, 2003

Pancreatic polypeptide update: its roles in detection of the trait for multiple endocrine adenopathy syndrome, type I and pancreatic polypeptide-secreting tumors. Surgery 94(6): 1028-1037, 1983

Multiple nonfunctional pancreatic islet cell tumor in multiple endocrine neoplasia type I. A case report. Acta Pathologica Japonica 38(5): 667-682, 1988

Pancreatic polypeptide and gastrin after a meal test in patients with multiple endocrine neoplasia type 1. Digestion 59(3): 220, May-June, 1998

Large and asymptomatic pancreatic islet cell tumor in a patient with multiple endocrine neoplasia type 1. Endocrine 13(3): 263-266, 2001

Management of pancreatic endocrine tumors in patients with multiple endocrine neoplasia type 1. Surgical Oncology Clinics of North America 7(4): 881-891, 1998

EUS detection of pancreatic endocrine tumors in asymptomatic patients with type 1 multiple endocrine neoplasia. Gastrointestinal Endoscopy 58(4): 531-535, 2003

Presymptomatic diagnosis of pancreatic endocrine tumors in patients with multiple endocrine neoplasia type I using endoscopic ultrasound. Gastroenterology 122(4 Suppl 1): A 566, April, 2002

Pathologic study with immunohistochemistry of 61 pancreatic endocrine tumors in 16 patients suffering from multiple endocrine neoplasia type I (MEN I). Review of the literature. Annales de Pathologie 16(3): 167-173, 1996